Keating Financial Advisory Services, Inc.
Position in DNLI — Denali Therapeutics Inc.
CIK 2103443
MANHATTAN, KS
Position in DNLI
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$694
+$61 QoQ
Shares Held
27
-18.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#271
of 290 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Keating Financial Advisory Services, Inc. holds $1,970,730 across 102 Biotechnology names. DNLI ranks #66 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
10,863 | $591,055 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
559 | $277,672 | |
| 3 | ACHV |
Achieve Life Sciences, Inc.
|
24,911 | $162,668 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
203 | $126,578 | |
| 5 | DYN |
Dyne Therapeutics, Inc.
|
5,112 | $113,537 | |
| 6 | PRQR |
ProQR Therapeutics N.V.
|
47,552 | $88,446 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
2,065 | $80,555 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
975 | $55,789 |
All Filings in DNLI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $694 | 27 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $633 | 33 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $330 | 20 | Shares | Sole | 2026-02-09 | |
| No filing history on record for this holder in this stock. | ||||||